常山药业
(300255)
| 流通市值：221.06亿 | | | 总市值：221.40亿 |
| 流通股本：9.18亿 | | | 总股本：9.19亿 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 475,824,544.14 | 256,104,391.71 | 875,132,346.58 | 681,221,459.23 |
| 营业收入 | 475,824,544.14 | 256,104,391.71 | 875,132,346.58 | 681,221,459.23 |
| 二、营业总成本 | 504,881,082.96 | 258,653,057.22 | 1,068,085,647.98 | 764,791,820.51 |
| 营业成本 | 372,970,912.63 | 193,106,895.06 | 742,718,973.25 | 572,805,300.05 |
| 税金及附加 | 5,327,940.73 | 2,493,696.69 | 12,528,154.61 | 9,594,954.46 |
| 销售费用 | 7,345,506.02 | 3,541,355.96 | 49,586,839.83 | 15,383,124.36 |
| 管理费用 | 53,806,720.41 | 27,220,319.72 | 136,856,560.78 | 76,760,352.99 |
| 研发费用 | 15,924,184.43 | 7,232,913.96 | 34,080,032.01 | 24,568,492.79 |
| 财务费用 | 49,505,818.74 | 25,057,875.83 | 92,315,087.5 | 65,679,595.86 |
| 其中:利息费用 | 45,379,075.66 | 21,816,957.16 | 96,906,831.85 | 68,489,516.51 |
| 其中:利息收入 | 145,558.61 | 117,282.93 | 1,930,605.42 | 1,398,745.35 |
| 三、其他经营收益 | | | | |
| 加:投资收益 | - | - | 1,671,766.1 | 1,671,766.1 |
| 资产处置收益 | -6,296.23 | - | -7,377.37 | 17,641.19 |
| 资产减值损失(新) | - | - | -112,651,108.45 | 14,434,330.49 |
| 信用减值损失(新) | 560,212.28 | 1,719,642.62 | -54,210,722.24 | 7,201,497.18 |
| 其他收益 | 8,881,855.94 | 5,574,796.13 | 7,837,849.91 | 5,567,369.76 |
| 四、营业利润 | -19,620,766.83 | 4,745,773.24 | -350,312,893.45 | -54,677,756.56 |
| 加:营业外收入 | 563,300.63 | 464,667.83 | 1,199,271.1 | 609,746.12 |
| 减:营业外支出 | 114,241.12 | 7,526.23 | 6,777,980.2 | 272,200.01 |
| 五、利润总额 | -19,171,707.32 | 5,202,914.84 | -355,891,602.55 | -54,340,210.45 |
| 减:所得税费用 | 2,584,361.49 | 1,822,510.57 | 11,569,526.96 | 2,643,421.59 |
| 六、净利润 | -21,756,068.81 | 3,380,404.27 | -367,461,129.51 | -56,983,632.04 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | -21,756,068.81 | 3,380,404.27 | -367,461,129.51 | -56,983,632.04 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | -16,761,782.73 | 5,871,019.93 | -357,895,551.22 | -44,817,386.29 |
| 少数股东损益 | -4,994,286.08 | -2,490,615.66 | -9,565,578.29 | -12,166,245.75 |
| 扣除非经常损益后的净利润 | -21,861,036.46 | 1,272,524.57 | -356,952,357.57 | -47,687,001.24 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | -0.02 | 0.01 | -0.39 | -0.05 |
| (二)稀释每股收益 | -0.02 | 0.01 | -0.39 | -0.05 |
| 八、其他综合收益 | 211,499.49 | 132,930.07 | -219,716.12 | -254,189.96 |
| 归属于母公司股东的其他综合收益 | 211,499.49 | 132,930.07 | -219,716.12 | -254,189.96 |
| 九、综合收益总额 | -21,544,569.32 | 3,513,334.34 | -367,680,845.63 | -57,237,822 |
| 归属于母公司股东的综合收益总额 | -16,550,283.24 | 6,003,950 | -358,115,267.34 | -45,071,576.25 |
| 归属于少数股东的综合收益总额 | -4,994,286.08 | -2,490,615.66 | -9,565,578.29 | -12,166,245.75 |
| 公告日期 | 2026-08-26 | 2026-04-29 | 2026-04-29 | 2025-10-30 |
| 审计意见(境内) | | | 标准无保留意见 | |